ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mirvetuximab soravtansine

Also written as “Mirvetuximab Soravtansine”, “Mirvetuximab soravtansine” and “TAK-853”.

Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms · Neoplasms, led by 5 companies.

Drug pageMirvetuximab soravtansine: every studyMany companies study it; this page follows only the 15 they lead. All 28 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 10, 201515 company-led studies, 8 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only115 open or runningphase 3since Dec 10, 2015May 30, 2012Nov 2026phase 2 · NCT05456685
AGO Research11 open or runningphase 2since Feb 10, 2020Feb 10, 2020none ahead
Huadong Medicineits history only10 open or runningphase 3since Nov 14, 2022Nov 14, 2022none ahead
Pheast Therapeuticsits history only11 open or runningphase 1since Feb 10, 2025Feb 10, 2025Apr 2029phase 1 · NCT06840886
Takedaits history only11 open or runningphase 2since Apr 26, 2024Apr 26, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AGO Research only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named mirvetuximab soravtansineINNProposed as its International Nonproprietary Name in WHO's List 113 · before, TAK-853
  2. Feb 10, 2020First study: phase 2 study in Recurrent Epithelial Ovarian, Fallopian or Peritoneal CarcinomaFirst studyNCT04274426 · 136 enrolled · Germany

TargetBeta

FOLR1 →read by rule
“An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) ”NCIt, by rule
“Folate receptor alpha binding agent”ChEMBL 37, by rule

Other programs on FOLR1

ProgramCompanyFurthest phaseStudies
rinatabart sesutecanruleGenmabphase 39
torvutatug samrotecanAstraZenecaphase 35
sofetabart mipitecanEli Lillyphase 32
opugotamig olatansineAbbViephase 22
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901AbbViephase 11
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleteneoseven-incphase 11

Studies

The one study AGO Research leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04274426Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma · Germany2Active, not recruitingDec 3, 2025136

How it is read

Names in the registry

  • “Mirvetuximab Soravtansine”, 8 entries
  • “Mirvetuximab soravtansine”, 5 entries
  • “TAK-853”, 1 entry
  • “Mirvetuximab soravtansine plus Bevacizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.